Abiraterone
Approved · EMAAlso known as Abirtega, Akeega, Yonsa, Zytiga+3 more
Abirtega, Akeega, Yonsa, Zytiga, Abiraterona, 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol, Abiraterone Acetate.
Recent clinical, regulatory, research and industry developments relating to this drug.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Approval: Abiraterone Mylan (EMA)
Approval: Abiraterone Krka (EMA)
Approval: Abiraterone Accord (EMA)
Accelerated approval: Zytiga (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Abiraterone Mylan is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men… Show full indicationShow less
Abiraterone Mylan is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Indication: Abiraterone Krka is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in… Show full indicationShow less
Abiraterone Krka is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Indication: Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men… Show full indicationShow less
Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine3
- Cancer biology & medicine1
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Nature communications1
- Proceedings of the National Academy of Sciences of the United States of America1
- The Lancet. Oncology1
- Fizazi K3
- Abida W2
- Beltran H2
- de Bono J2
- Heidenreich A2
- Mateo J2
- Nolè F2
- Piulats JM2
- Memorial Sloan Kettering Cancer Center2
- Barbara Ann Karmanos Cancer Institute1
- Barretos Cancer Hospital1
- Broad Institute1
- Catalan Cancer Institute1
- Cliniques Universitaires Saint-Luc1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Abiraterone, with 4 overlapping disease areas.
Studied across 3 of the same disease areas as Abiraterone in the shared literature.
Studied across 3 of the same disease areas as Abiraterone in the shared literature.
Studied across 3 of the same disease areas as Abiraterone in the shared literature.
Studied across 2 of the same disease areas as Abiraterone in the shared literature.
Studied across the same disease area as Abiraterone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.